이스라엘 - 히브리어 - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).

이스라엘 - 히브리어 - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).

이스라엘 - 히브리어 - Ministry of Health

teva pharmaceutical indust.ltd - palonosetron as hydrochloride 0.05 mg / 1 ml - solution for injection - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).

이스라엘 - 히브리어 - Ministry of Health

rafa laboratories ltd - potassium citrate 0.43 g / 5 ml; potassium gluconate 1.4 g / 5 ml - solution (oral) - combinations - prevention and treatment of hypokalemia.

이스라엘 - 히브리어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

이스라엘 - 히브리어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

이스라엘 - 히브리어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu/ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

이스라엘 - 히브리어 - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - apixaban - טבליות מצופות פילם - apixaban 2.5 mg - apixaban - apixaban - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ? ii).

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - apixaban - טבליות מצופות פילם - apixaban 5 mg - apixaban - apixaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ? ii).